In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée.
XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes and associated symptoms in adults, children, and infants.
Publication of a systematic review and meta-analysis on the efficacy of gelatin tannate in acute diarrhea in children.
Aim: To investigate by meta-analysis the efficacy of gelatin tannate (GT), a mucosal barrier protector, in children with acute gastroenteritis.
Conclusion: GT significantly (p < 0.01) reduced stool frequency at 12 h as well as the number of patients with diarrhea or liquid stools at 24 h (p < 0.01), compared with placebo.
No adverse events were reported in any of the RCTs analyzed. The unique mechanism and lack of systemic absorption of GT make this device an interesting addition to the current armamentarium for treating acute gastroenteritis in children.
As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018.
Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information.
Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.
